Drugs and Druggists' Sundries Merchant Wholesalers (NAICS 4242)

A Histometrics industry primer for public- and private-market investors

Short primer — single-child pass-through. In the North American Industry Classification System (NAICS), this four-digit industry group contains exactly one five-digit industry, 42421, and is defined identically to it. This page gives the level's own federal figures and a plain-language orientation; for full detail — the investable names, economics, regulation, and risks — read the 42421 primer (which in turn resolves to the single six-digit national industry, 424210).

1. Overview

NAICS 4242 is the U.S. drug-distribution "middle mile": the wholesalers that buy prescription drugs, generics, vaccines, and related health-and-beauty goods from manufacturers and deliver them to the pharmacies, hospitals, clinics, and doctors' offices that dispense them. Almost every prescription filled in America passes through one of these firms, usually within a day of being ordered [1]. The Healthcare Distribution Alliance (HDA), the industry's trade body, describes its member distributors as connecting roughly 1,400 manufacturers with 450,000 pharmacies, providers, and other sites of care, moving more than 10 million medicines, vaccines, and other healthcare products every day [2].

It is a defensive, volume-driven, razor-thin-margin logistics business sitting on one of the steadiest demand curves in the economy — sick and aging people need medicine regardless of the business cycle. And it is a genuine oligopoly: three firms — McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health — handle more than 90% of U.S. prescription-drug distribution by revenue [1]. That structure is settled rather than new: Federal Trade Commission workshop data put the same three at roughly 85% combined as far back as 2017 (McKesson 32.7%, AmerisourceBergen 31.6%, Cardinal 20.7%) [3].

2. What's inside — and why this level equals its one child

NAICS is a nested hierarchy that adds digits as it narrows: a four-digit industry group splits into one or more five-digit industries, each of which splits into one or more six-digit national industries. When a level is not subdivided, its single child simply repeats the code with a trailing digit. That is the case twice over here: 4242 has one child, 42421, which in turn has one child, 424210 — all three codes describe the same scope. There is nothing in 4242 that is not in 42421 (and 424210), so every figure, dynamic, and risk on this page belongs to that single industry.

Because the level and its child are identical, this primer does not repeat the child's full analysis. The one child covers merchant wholesalers of pharmaceuticals, biologicals, vaccines and blood derivatives, in-vitro diagnostics, botanicals, and "druggists' sundries" — vitamins, supplements, cosmetics, toiletries, and first-aid goods [4]. "Merchant wholesaler" means the firm takes ownership of the goods (buys and resells at its own risk), unlike a broker or commission agent that never holds title. See 42421 for the full definition, the exclusions (medical-surgical equipment in 423450, retail pharmacies in 446110/456110, and drug manufacturing in 325412 sit in other codes), and the ownership mix.

3. Size

Federal statistics for NAICS 4242 (our ground-truth figures). Because this level equals its one child, these are the same values reported for 42421 and 424210.

The firm count hides how lopsided the revenue base is. This is the one statistic the Census reports natively at this level rather than at the child's: for 2023 it counted 9,689 employer and nonemployer firms under NAICS 4242 with $1.253 trillion of sales — but 2,500 of those were nonemployers generating only $395.3 million between them, while 7,189 employer firms accounted for essentially the entire $1.2529 trillion [8]. A long tail by headcount; almost no tail by dollars. (The 9,689 figure is not comparable with the 6,632 in the table above: different year, and the 2023 series adds nonemployers.)

Two honest caveats. First, receipts are gross flow-through, not value added: that ~$1.28 trillion is essentially the cost of the medicine passing through, booked as revenue. The industry keeps only pennies on each dollar, so the figure vastly overstates the economic value the sector captures — and it should not be read as drug spending. Different measures at different scopes and valuation points give very different numbers: the Centers for Medicare & Medicaid Services (CMS) put U.S. retail prescription-drug spending at $467.0 billion in 2024 [9], while HDA measured $666 billion of prescription sales through traditional distributors in 2022 [10]. None of the three is a substitute for the others.

Second, this is not an undercounted industry — the opposite of the sole-proprietor trades where the government misses small operators. Here a handful of large public firms dominate and are captured well, so the receipts figure over-states, not under-states, the sector's true economic weight. (One nuance: large integrated retailers and pharmacy-benefit managers self-distribute some volume through captive networks, and some specialty and limited-distribution drugs ship manufacturer-direct, landing in retail or manufacturing statistics rather than here — so 4242 does not capture 100% of the medicine flowing through the country [4].)

4. Investable universe — where the value concentrates

With only one child, there is no "spread across sub-industries" to map: all of the level's value sits in 42421, and within it, in three large-cap names on the New York Stock Exchange (NYSE) with combined fiscal-2025 revenue near $900 billion — McKesson (MCK) at $359.1 billion, up 16% [11]; Cencora (COR) at $321.3 billion, up 9.3% [12]; and Cardinal Health (CAH) at $222.6 billion, down 2% on the expiration of its OptumRx distribution contracts but up roughly 18% excluding them [13]. Their fiscal years end in different months (McKesson in March, Cardinal in June, Cencora in September), so headline comparisons need care, and none is a pure play on this code — each also books medical-surgical, services, technology, and international revenue that falls outside 4242 [11][14][15].

Scale has not bought bargaining power over customers, a point the child primer now quantifies. McKesson reported that its ten largest customers were about 73% of fiscal 2026 consolidated revenue, with CVS Health alone at roughly 24% [14]; Cardinal reported CVS Health at 30% of fiscal 2025 revenue [15]. Below the Big Three is a long tail of private and cooperatively owned regional wholesalers (Morris & Dickson, Smith Drug, Value Drug and peers) and manufacturer-owned distributors such as Teva's Anda [16] — a fringe where compliance is the live risk, as Morris & Dickson's 2024 DEA settlement over unusually large opioid orders shows [17]. The full name-by-name table, market caps, yields, and the adjacent distributors are in the 42421 primer, Section 4.

5. How the money works

Revenue is a poor guide to profit because most of it is pass-through drug cost. Operating margins run about 1–2% on low-single-digit gross margins (roughly 3.5%); owners make money on scale, logistics efficiency, product mix, and working-capital float, not on markup [1][18]. Public filings bear that out at segment level with remarkable consistency across all three firms: McKesson's North American Pharmaceutical segment earned $3.658 billion on $336.7 billion of fiscal 2026 revenue (1.09%) [14]; Cencora's U.S. Healthcare Solutions segment $3.575 billion on $291.0 billion (~1.23%) [19]; Cardinal's Pharmaceutical and Specialty Solutions segment $2.258 billion on $204.6 billion (~1.10%) [15]. HDA's survey of large traditional distributors reported a 0.4% after-tax net margin for the 2022 operating year, with inventory held an average of 24 days [10].

The real profit engine is generics: generics and biosimilars were only ~15% of distribution revenue but roughly 77% of gross profit in 2022 [20]. Two profit pools (buy-side distribution-service fees tied to branded list prices, and sell-side generic spread), plus working-capital float and a growing specialty/"buy-and-bill" channel, drive economics. See 42421, Section 5, for the full mechanics.

6. Demand drivers

The tailwinds are structural: rising aggregate drug spending and prescription volume (U.S. drug expenditures rose ~10.2% to about $805.9 billion in 2024, driven mainly by utilization) [21]; CMS-measured retail prescription spending of $467.0 billion in 2024, up 7.9% and projected to grow 5.7% a year through 2034 — the fastest of its major health-spending categories [9]; an aging population; the GLP-1 (glucagon-like peptide-1 receptor agonist) weight-loss and diabetes boom, roughly $132 billion of 2025 sales and now the largest and fastest-growing drug category [22]; the shift toward specialty and biologic drugs, where HDA cites IQVIA at $417 billion of U.S. specialty-medicine sales in 2024, up 12% [23]; and a steady wave of generic and biosimilar launches that is margin-accretive for distributors [20][10].

One caution the child primer now makes explicit and this level should carry: volume is not the same as profit. Cardinal disclosed that growing GLP-1 sales significantly increased revenue in the six months ended December 2025 but did not meaningfully contribute to segment profit [24]. Read segment profit and mix, not gross drug sales. Detail in 42421, Section 6.

7. Regulation

Drug distribution is one of the most heavily regulated links in health care. Distributors register with the Drug Enforcement Administration (DEA) and run anti-diversion and suspicious-order monitoring; comply with the Drug Supply Chain Security Act (DSCSA) package-level "track-and-trace" regime (the wholesaler deadline fell on August 27, 2025, and the temporary FDA exemption expired with it, making serialization and exception management permanent obligations) [25]; answer to the Food and Drug Administration (FDA) and to state boards of pharmacy that license every distributor; carry opioid-settlement obligations including a national controlled-substance data clearinghouse [26]; and face drug-pricing reform (the Inflation Reduction Act's Medicare price negotiation and Part D redesign) that pressures the branded fee model. These rules cut asymmetrically: they are a fixed cost that reinforces the incumbents' scale advantage and disadvantages undercapitalized regional firms. Full treatment in 42421, Section 7.

8. Consolidation

Horizontal consolidation is essentially finished — three firms, more than 90% of the prescription-drug channel [1]. The federal concentration figures above look milder (a CR4 of 50.3% and an HHI of 805.7, which antitrust agencies technically call "unconcentrated") because the Census counts every firm booking receipts under this code — including a long tail of generic, cosmetic, supplement, and sundry wholesaling — and excludes the medical-surgical, services, and international revenue the Big Three report elsewhere, while the "90%-plus" refers to the narrow prescription-drug-distribution market they dominate. Both are correct at different scopes: treat the federal numbers as the honest floor on measured concentration [5].

The active frontiers now are customer power and vertical integration. On the customer side, a single mega-contract can move roughly $40 billion of revenue — the OptumRx shift that dented Cardinal's fiscal 2025 and lifted McKesson's is the case in point [11][13]. On the vertical side, the Big Three have spent more than $16 billion buying physician-practice management-services organizations in oncology, gastroenterology, urology, and ophthalmology to steer that drug purchasing to themselves [27]. Portfolio focus is moving the same direction: McKesson intends to spin off its Medical-Surgical Solutions segment by the second half of 2027 to concentrate on pharmaceutical distribution and oncology services [11]. See 42421, Section 8.

9. Risks

The headline risks carry over intact: the multi-year opioid-settlement cash drain (up to ~$21 billion across the three distributors over 18 years, part of a ~$26 billion deal that also included Johnson & Johnson) [26][28]; drug-pricing reform eroding the branded fee income tied to list prices and shrinking inventory-appreciation gains; customer concentration, now quantified — CVS Health alone is ~24% of McKesson's and 30% of Cardinal's revenue [14][15]; thin margins around 1–2% that magnify any cost, mix, credit, or contract shift; antitrust scrutiny of the physician-practice push; and cyber/supply-chain shocks. The children add a longer-dated one worth carrying up: disintermediation from manufacturer-direct-to-patient models, cost-plus pharmacies, and Amazon Pharmacy — though regulated physical handling, financing, returns, and package-level traceability make full disintermediation hard. Full list in 42421, Section 9.

10. How to invest and outlook

Because this level is its one child, the playbook is identical. Public route: the cleanest exposure is the three NYSE large-caps — MCK, COR, CAH — defensive, volume-driven compounders with low dividend yields (under ~1%; McKesson ~0.3%, Cardinal ~0.9%) and returns driven by operating-income growth and heavy buybacks [29]; there is no dedicated drug-distribution exchange-traded fund (ETF), but broad health-care and total-market index funds already hold them, and any segment analysis needs adjusting for the non-4242 businesses each carries [14][15]. Private route: direct ownership means the regional and independent wholesalers, most private or cooperatively owned and rarely for sale, where diligence centers on state licensing, DEA registrations, suspicious-order systems, serialization capability, customer concentration, and working-capital financing [16] — though private capital has largely migrated to the downstream specialty-pharmacy and physician-practice assets the distributors themselves are buying [27]. Outlook: a steady, cash-generative, defensively positioned industry prized for reliability rather than growth or yield, insulated by scale, licensing, and compliance moats — with drug-pricing reform, contract renewals, opioid outflows, and the profitability (or antitrust cost) of vertical integration as the watch-items. For the complete how-to-invest and outlook discussion, read the 42421 primer.

---

Sources

Drawn from the child primer (42421); the size figures are our ground-truth federal statistics for NAICS 4242.

1. IntuitionLabs. "US Drug Wholesalers: How McKesson, Cencora & Cardinal Control 90%+ of Distribution." 2025. https://intuitionlabs.ai/articles/drug-wholesaler-market-concentration
2. Healthcare Distribution Alliance. "Understanding Healthcare Distributors and Their Role" (manufacturers, sites of care, daily volume). 2026. https://www.hda.org/perspectives/2026/02/understanding-healthcare-distributors-and-their-role/
3. Federal Trade Commission. "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics" workshop slides, page 100 (2017 market shares). 2017. https://www.ftc.gov/system/files/documents/public_events/1255653/understanding_competition_in_prescription_drug_markets_workshop_slides_11-8-17.pdf
4. NAICS Association. "NAICS Code 424210 — Drugs and Druggists' Sundries Merchant Wholesalers" (definition and cross-references). 2022. https://www.naics.com/naics-code-description/?code=424210
5. U.S. Census Bureau. 2022 Economic Census, Concentration & Selected Statistics (NAICS 424210 / 42421 / 4242): receipts, firm count, CR4/CR8/CR20/CR50, HHI. 2022. https://www.census.gov/programs-surveys/economic-census.html
6. U.S. Census Bureau. County Business Patterns, 2023 (NAICS 424210 / 42421 / 4242): establishments, employment, payroll. 2023. https://www.census.gov/programs-surveys/cbp.html
7. U.S. Small Business Administration. Table of Small Business Size Standards (NAICS 424210 = 250 employees). 2023. https://www.sba.gov/document/support-table-size-standards
8. U.S. Census Bureau. 2023 Nonemployer Statistics by Demographics (NAICS 4242): employer and nonemployer firm counts and sales. 2023. https://data.census.gov/table/ABSNESD2023.AB00MYNESD01C?codeset=naics~4242&g=010XX00US
9. Centers for Medicare & Medicaid Services. National Health Expenditure Fact Sheet (retail prescription drug spending $467.0B in 2024; 5.7% projected annual growth 2025–2034). 2025. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
10. Healthcare Distribution Alliance. 2022 Operating-Year Factbook Summary ($666B prescription sales, 0.4% after-tax net margin, 24 inventory days, biosimilar share). 2023. https://hda.org/newsroom/2023/hda-factbook-rx-sales-through-traditional-healthcare-distributors-increase/
11. McKesson Corporation. "McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions." 2025. https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-reports-fiscal-2025-fourth-quarter-and-full-year-results/
12. Cencora, Inc. "Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results." 2025. https://investor.cencora.com/news/news-details/2025/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results/default.aspx
13. Cardinal Health, Inc. Fiscal 2025 fourth-quarter and full-year results (Form 8-K) and FY25 Annual Report. 2025. https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-FY25-annual-report.pdf
14. McKesson Corporation. Fiscal 2026 Form 10-K (customer concentration, segment results, distribution network). 2026. https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm
15. Cardinal Health, Inc. Fiscal 2025 Form 10-K (CVS concentration, segment results). 2025. https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm
16. DrugZone / Morris & Dickson. "Top Pharmaceutical Distributors in the USA" and Morris & Dickson company profile (regional/independent distributors). 2025. https://www.drugzone.com/blog/top-7-pharmaceutical-distributors-in-the-usa
17. Drug Enforcement Administration. "DEA Announces Settlement with Morris & Dickson Co., LLC." 2024. https://www.dea.gov/press-releases/2024/02/07/dea-announces-settlement-morris-dickson-co-llc
18. FinancialContent. "McKesson (MCK): A Deep-Dive into the Backbone of the Healthcare Supply Chain" (operating and gross margin figures). 2026. https://markets.financialcontent.com/stocks/article/finterra-2026-3-18-mckesson-mck-a-deep-dive-into-the-backbone-of-the-healthcare-supply-chain
19. Cencora, Inc. Fiscal 2025 results filed with the SEC (U.S. Healthcare Solutions segment). 2025. https://www.sec.gov/Archives/edgar/data/1140859/000114085925000128/exhibit991-q42025.htm
20. Drug Channels (Adam J. Fein). "How the Biosimilar Boom Boosts Drug Wholesalers' Profits" (generic share of revenue vs. gross profit). 2022. https://www.drugchannels.net/2022/10/how-biosimilar-boom-boosts-drug.html
21. ASHP / American Journal of Health-System Pharmacy. "National trends in prescription drug expenditures and projections" (U.S. drug spending +10.2% to $805.9B in 2024). 2024–2025. https://news.ashp.org/news/ashp-news/2025/04/24/us-drug-spending-up-10-in-2024-with-weight-loss-drugs-remaining-top-driver
22. Towards Healthcare. "GLP-1 Drugs Market Sizing" (GLP-1 ~$132B 2025 sales; specialty share of drug spend). 2025. https://www.towardshealthcare.com/insights/glp1-drugs-market-sizing
23. Healthcare Distribution Alliance. "Specialty Distributors: Meeting the Challenges of a Growing Market" (IQVIA specialty-medicine sales $417B in 2024). 2025. https://hda.org/newsroom/2025/december/specialty-distributors-meeting-the-challenges-of-a-growing-market/
24. Cardinal Health, Inc. Form 10-Q (GLP-1 revenue vs. profit impact, six months ended December 2025). 2026. https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/cah-20251231.htm
25. Körber Supply Chain. "DSCSA Enforcement has begun: What the May 27, 2025 deadline means" (wholesaler deadline August 27, 2025). 2025. https://koerber-supplychain.com/about-us/blog/dscsa-enforcement-has-begun/
26. National Opioids Settlement. "Executive Summary" (distributor settlement terms and clearinghouse). 2021–2024. https://nationalopioidsettlement.com/executive-summary/
27. Drug Channels (Adam J. Fein). "The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers' Vertical Integration with Physician Practices" (>$16B MSO acquisitions). 2025. https://www.drugchannels.net/2025/10/the-future-of-buy-and-bill-market.html
28. CNBC. "Big 3 U.S. drug distributors, Johnson & Johnson reach landmark $26 billion opioid settlement." 2021. https://www.cnbc.com/2021/07/21/drug-distributors-jj-reach-landmark-26-billion-opioid-settlement-.html
29. American Association of Individual Investors (AAII). "Which Is a Better Investment, Cardinal Health Inc or McKesson Corp Stock?" (market caps and dividend yields, early 2026). 2026. https://www.aaii.com/investingideas/article/25359-which-is-a-better-investment-cardinal-health-inc-or-mckesson-corp-stock